Serum Her-2/neu and survivin levels and their relationship to histological parameters in early-stage breast cancer
| dc.contributor.author | Goksel G. | |
| dc.contributor.author | Taneli F. | |
| dc.contributor.author | Uslu R. | |
| dc.contributor.author | Ulman C. | |
| dc.contributor.author | Dinc G. | |
| dc.contributor.author | Coskun T. | |
| dc.contributor.author | Kandiloglu A.R. | |
| dc.date.accessioned | 2025-04-10T11:16:59Z | |
| dc.date.available | 2025-04-10T11:16:59Z | |
| dc.date.issued | 2007 | |
| dc.description.abstract | This study was conducted to investigate the serum levels of her-2/neu and survivin in patients with early-stage breast cancer and their relationship with known histological parameters. Forty-one patients with early-stage breast cancer were investigated. Serum samples were collected from patients on their first admission before adjuvant chemotherapy, and from healthy controls. Serum her-2/neu and survivin levels were determined using an enzyme-linked immunosorbent assay. There was no difference in the levels of serum her-2/neu and survivin between the breast cancer patients and the control group. Serum her-2/neu concentration showed moderate correlations with disease stage and the Ki-67 level, and the serum survivin level showed a moderate correlation with progesterone receptor concentration. Serum levels of her-2/neu and survivin were not significantly related to age and histological parameters in patients with early-stage breast cancer. However, much research continues on the prognostic value of serum her-2/neu and survivin levels, and important new knowledge may ultimately emerge. Copyright © 2007 Cambridge Medical Publications. | |
| dc.identifier.DOI-ID | 10.1177/147323000703500201 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14701/52266 | |
| dc.publisher | Cambridge Medical Publications | |
| dc.title | Serum Her-2/neu and survivin levels and their relationship to histological parameters in early-stage breast cancer | |
| dc.type | Article |